Pharmaceutical Change Management: what 19,950 assessments reveal
Your organization is excellent at deciding. That is exactly where adoption leaks.
Pharmaceutical change management is the discipline of turning an approved change into adopted practice across R&D, manufacturing, quality, and commercial teams. Unlike awareness-based frameworks, the Accelerating Implementation Methodology (AIM) measures implementation history first, then builds readiness through observable behavior. IMA Worldwide's pharmaceutical benchmark shows precisely where that gap opens.
What does the pharmaceutical implementation record actually show?
IMA Worldwide evaluated its Implementation History Assessment (IHA) data from 2001 on. The assessment asks people who lived through previous changes fifty questions about how those changes actually landed, and scores the result across ten sections. The pharmaceutical cut of that archive covers 19,950 responses from 54 pharmaceutical organizations.
The first finding is the one most likely to surprise a pharmaceutical executive: pharma is not a laggard. Its mean readiness score of 59.8 sits almost exactly on the all-industry average of 59.7. What separates pharmaceutical organizations is not the overall score. It is the shape of the score.
Figure 1. Section scores for the pharmaceutical cohort, sorted lowest to highest. Every section sits in a narrow band between 54 and 67, which is why the overall average hides the story. Involvement is the floor and Structure is the ceiling, and Involvement is the only section where pharmaceutical organizations sit measurably below other industries.
Figure 2. Roughly 3 in 100 pharmaceutical respondents describe an organization that scores High on readiness to implement, while 49.3 percent score Low or Very Low. This distribution has held across two decades and 54 companies, which is what makes it a predictable structural condition rather than a verdict on any one organization.
How to read this benchmark. These are organizations that engaged IMA Worldwide, so the cohort is client-weighted rather than market-representative, and a single large employer contributes roughly a third of the responses. The window runs 2001 to 2023, with most volume between 2008 and 2014. Read it as a durable pattern across 54 pharmaceutical organizations, not as a current-year census of the industry.
Why do pharmaceutical transformations stall after go-live?
Look at the individual questions rather than the sections, and the pattern sharpens into something specific and actionable. Of all fifty items in the assessment, the two that pharmaceutical organizations score highest are about governance, and the two they score lowest are about participation.
| Assessment item | Pharma | All others | What it measures |
|---|---|---|---|
| Responsibility is defined | 3.65 | 3.65 | People know who owns what |
| Authority is defined | 3.46 | 3.52 | Decision rights are clear |
| Involved in implementation | 2.63 | 2.68 | A say in how it rolls out |
| Involved in design | 2.47 | 2.58 | A say in what gets built |
| Number of changes is manageable | 2.42 | 2.48 | Capacity to absorb change |
| Involved in decisions | 2.34 | 2.47 | A say in whether it happens |
Involved in decisions, at 2.34, is the single lowest-scoring item of all fifty, and it is also the widest gap between pharmaceutical organizations and everyone else. Involved in design is the second widest. Read alongside the two highest items, the sequence describes a recognisable operating pattern:
A pharmaceutical organization defines the change carefully, assigns it cleanly, resources it properly, and then discovers that the people expected to work differently were never part of building the thing they are now being asked to adopt. The plan is sound. The governance is real. The adoption is thin.
According to the AIM framework, that is the textbook definition of installation rather than implementation: the system goes live, the SOP is approved, the org chart is redrawn, and the behavior does not follow. Installation is the change being put in place. Implementation is people actually working the new way. Pharmaceutical organizations are unusually good at the first and structurally exposed on the second.
Figure 3. The pharmaceutical sequence. Every governed step scores at or near the top of the instrument. The one step that is not governed, bringing people into the decision and the design, scores at the bottom, and it sits directly between a system that is live and people who actually work the new way.
Change load compounds it. Manageable number of changes, at 2.42, is the second-lowest item in the cohort. When teams are already absorbing more concurrent change than they have capacity for, skipping the involvement step feels like the efficient choice. It is the most expensive one.
This is not a pharmaceutical failing. Defined responsibility and defined authority scoring at the top of a fifty-item instrument is a genuine organizational strength, and it is the direct product of operating in a regulated environment where accountability must be documented. The involvement gap is the predictable shadow of that strength, which is precisely why it responds to a deliberate method.
What makes change management different in the pharmaceutical industry?
IMA Worldwide's pharmaceutical white paper, Beyond Drug Discovery, names four cultural conditions that push pharmaceutical organizations toward installation. It was written from field observation across pharmaceutical engagements, and is set out in full in why internal change in pharma fails. The assessment data arrives at the same conclusion from an entirely separate direction, which is the strongest form of corroboration available.
Sponsors are scientists first
Leaders trained in the scientific method are trained to withhold commitment until the evidence is complete. That is exactly right in research and exactly wrong in sponsorship, where visible commitment has to precede proof. It shows up in the data as sponsorship that is competent on paper and quiet in the room.
Caution is correctly rewarded
In an environment where a mistake can mean a patient harmed or a regulatory finding, risk aversion is a feature. The cost is that rewards risk taking scores 2.65 in the pharmaceutical cohort, one of its weakest items, so people default to the documented behavior rather than the new one.
Heavy matrixing spreads authority
Global functions, regional affiliates, sites, and therapeutic areas each hold part of the decision. Sponsorship has to cascade through every one of them, and any gap becomes a place where the change quietly stops. Turf guarding is rare scores 2.46, the third-lowest item in the cohort.
Project management capacity is scarce
Technical delivery consumes the available project resource, so the people-side plan is the first thing cut when timelines compress. The technical objective gets met and the human objective goes unowned, which is why human objectives scores 2.77 against a technical-objectives score well above it.
Figure 4. The four conditions are not abstractions. Each one leaves a fingerprint in the assessment: scientist-sponsors show up as weak establish commitment, scarce project resource as unowned human objectives, regulatory caution as low rewards risk taking, and heavy matrixing as turf guarding. All four sit below the midpoint of the scale.
What does AIM change for a pharmaceutical organization?
The Accelerating Implementation Methodology (AIM) was developed by Don Harrison, founder of IMA Worldwide, and is built on more than 40 years of field research. It exists to close exactly the gap the benchmark exposes. Four parts of the method map directly onto the pharmaceutical profile.
It measures before it trains
The Implementation History Assessment scores how change has actually landed in your organization before, because implementation history is the best available predictor of how the next change will go. You get your own version of the profile on this page, by site, function, or therapeutic area, instead of a generic maturity rating.
It treats readiness as five ordered elements
Readiness is built through Information, Willingness, Ability, Confidence, and Control, in that order. Control asks "did I have any say in this?", which is the precise element the pharmaceutical cohort scores lowest on. AIM makes it a planned work product rather than an afterthought.
It gives sponsors something concrete to do
Express, Model, Reinforce weights leadership behavior by impact: what a leader says carries roughly 1x, what a leader models 2x, and what a leader reinforces 3x. From it come the six tasks a sponsor cannot delegate, which is what a scientist-sponsor needs instead of an instruction to be more visible.
It runs alongside your delivery methods
AIM does not replace change control, validation, PMI, Agile, Lean, or SAFe. Change control governs the documented state of a validated system. AIM governs whether people adopt the new way of working once that documentation is approved. The two answer different questions and run in parallel.
| # | Non-delegable sponsor task | EMR level | Impact |
|---|---|---|---|
| 1 | Communicate the business case | Express | 1x |
| 2 | Participate in goal setting | Express | 1x |
| 3 | Allocate resources | Model | 2x |
| 4 | Align reward systems | Reinforce | 3x |
| 5 | Cascade to direct reports | Reinforce | 3x |
| 6 | Monitor progress constantly | Model | 2x |
According to IMA Worldwide's field research, active sponsorship of this kind is associated with a 2 to 3 times uplift in adoption over passive sponsorship, and reinforcement carries roughly three times the impact of communication. Adoption tends to fade within about 90 days of go-live without it, which is the window most pharmaceutical programs treat as the finish line. One global pharmaceutical manufacturer used AIM to facilitate a 70 million dollar SAP implementation delivered on time, under budget, and with no reduction in scope.
What do pharmaceutical teams say after certification?
Pharmaceutical organizations are among the most represented employers in the AIM accredited practitioner base. Attributions below are role and sector only, by convention.
"Asking for support in the specific way I was taught in the AIM Accreditation makes me more successful in all aspects of my work. I learned to phrase my asks in a way that gets the support I need from both Authorizing and Reinforcing Sponsors, and because of this skill I have been able to get more projects approved."
Change practitioner, global pharmaceutical company
"AIM provided me with insight into why many of our change implementation projects were failing. Most people leave out critical steps that would ensure success. This course highlights those key areas and lays out practical management tools."
Change lead, global pharmaceutical company
"It was a truly valuable experience that left me and the team extremely well-prepared to move forward with implementation. I received a request to pull together a presentation for our Authorizing Sponsor, and without this workshop that would have been impossible."
Senior director, global medical statistics, pharmaceutical company
How do you build change capability across a matrixed pharmaceutical organization?
A matrixed organization cannot buy adoption one project at a time, because the next project inherits none of it. Pharmaceutical organizations that get this right build an internal capability: a shared method, a scored toolkit, and certified people in every function that touches the change. These are the four entry points.
Start with a measured read
The Implementation History Assessment and the Implementation Risk Forecast give you your own version of the profile on this page, scored by site, function, or therapeutic area, before anyone is trained.
See the AIM toolkit and assessments
Certify an internal cohort
AIM Practitioner Certification builds the bench that carries the method into R&D, quality, manufacturing, and commercial. Practitioners learn on live initiatives, not in a workshop vacuum.
Explore AIM certification
Subscribe and license at enterprise scale
An enterprise subscription opens the full toolkit, assessments, and teaching materials, and Train the Trainer certification lets your own instructors teach AIM internally under one agreement.
See AIM licensing and subscription
See the full capability journey
The measured two-year path from baseline assessment to a Center of Excellence your own people run, with the assessment re-run at months 0, 12, and 24 so capability is proven rather than asserted.
Follow the AIM capability journeyWhere AIM is already applied in pharmaceutical organizations: clinical process improvement, R&D change, restructuring, Lean and Six Sigma programs, ERP and technology deployments, and merger and acquisition integration.
Common questions about pharmaceutical change management
Why do pharmaceutical transformations stall after go-live?
Pharmaceutical transformations most often stall because the people expected to work differently were never part of designing the change. Across 19,950 implementation assessments from 54 pharmaceutical organizations, the lowest scoring item of all fifty is being involved in the decision, at 2.34 on a 5 point scale, while defined responsibility and defined authority are the two highest. That combination produces a well governed plan that has no behavioral traction, which is the difference between installation and implementation.
What makes change management different in the pharmaceutical industry?
Four conditions specific to pharmaceutical organizations shape how change lands: sponsors who are scientists first and are trained to withhold commitment until evidence is complete, a regulatory culture where caution is correctly rewarded, heavy matrixing that spreads authority across functions and geographies, and scarce internal project management capacity. None of these are faults. Each one quietly pushes an organization toward installing a change rather than implementing it.
How many pharmaceutical organizations score as ready to implement change?
About 3 in 100. In the pharmaceutical cohort of the IMA Worldwide assessment archive, 3.1 percent of respondents describe an organization scoring High on implementation readiness, while 49.3 percent score Low or Very Low. The distribution has held steady across two decades and 54 companies, which makes it a predictable structural condition rather than a judgment about any one organization.
Can AIM be used alongside GxP validation and change control?
Yes. Change control governs the documented state of a validated system or process. The Accelerating Implementation Methodology (AIM) governs whether people actually adopt the new way of working once that documentation is approved. They answer different questions and run in parallel, which is why AIM is also used alongside PMI, Agile, Lean, and SAFe delivery methods rather than replacing them.
How do pharmaceutical teams get certified in AIM?
Pharmaceutical teams typically begin with an Implementation History Assessment to establish a baseline, then certify an internal cohort through AIM Practitioner Certification. Organizations running change at scale add an enterprise subscription for the toolkit and Train the Trainer certification so their own instructors teach AIM internally. Pharmaceutical organizations are already among the most represented employers in the accredited practitioner base.
What is the first step for a pharmaceutical organization new to AIM?
Start with a measured read rather than a training plan. The Implementation History Assessment scores how change has actually landed in your organization before, across ten sections including sponsorship, reinforcement, and involvement. It is the best available predictor of how the next change will go, and it tells you which capability step to enter at instead of assuming you need to start at the beginning.
See your own version of this benchmark
The profile on this page is the pharmaceutical average. The useful version is yours: scored by site, function, or therapeutic area, against 54 pharmaceutical organizations. Talk to IMA Worldwide about running the Implementation History Assessment on your portfolio.
Talk to IMA Worldwide about your portfolio See the assessments first